

MD Anderson at the 2024 SITC Annual Meeting

THE UNIVERSITY OF TEXAS
**MD Anderson
Cancer Center**
Making Cancer History®

MDAnderson.org/SITC

All sessions shown in CT.



| Pre-Conference Programs | | As of Nov. 8 |
|-------------------------|--|---|
| Thursday, Nov. 7 | | |
| 8:00 a.m.-5:30 p.m. | Primer on Tumor Immunology and Cancer Immunotherapy™ | George R. Brown Convention Center – Level 3 – Grand Ballroom C |
| 1:45-3:30 p.m. | Session III: Driving T Cells to the Tumor | |
| 3:05-3:30 p.m. | Immune Checkpoint Therapy: Biomarkers of Response and Resistance | Padmanee Sharma, M.D., Ph.D. |
| 3:45-5:25 p.m. | Session IV: Influencers of the Response to Immunotherapies | |
| 3:45-4:10 p.m. | Modulating the Tumor Microenvironment with T Cell Bispecifics | Sumit Subudhi, M.D., Ph.D. |
| 9:00 a.m.-5:00 p.m. | Immune Engineering Workshop: Building Bridges Between All Aspects of Engineering and Immuno-oncology | George R. Brown Convention Center – Level 3 – Grand Ballroom AB |
| 3:10-5:00 p.m. | Posters Abstract 1091: A STING agonist payloaded, tumor-specific antibody sensitizes murine pancreatic cancer to immune checkpoint blockade | Akash Boda |
| 12:40-1:40 p.m. | Meet-the-Expert Lunch | George R. Brown Convention Center – Level 3 – Meeting Room 332 |
| | Bioinformatics and Big Data: Career Development | Alexander Lazar, M.D., Ph.D. |
| | Career Paths for Physician Scientists | Tina Cascone, M.D., Ph.D. |
| | How to Navigate the Postdoc to PI Transition (Table 1) | Yu Lei, Ph.D., D.D.S. |
| | Translational Research: Human Samples to Lab and Back to the Clinic | Cara Haymaker, Ph.D. |
| 6:00-8:15 p.m. | Grant Writing Workshop | Marriott Marquis – Level 2 – Houston Ballroom, Salon 2 |
| 7:40-8:10 p.m. | Low-Preliminary Data Grants (DP5, R21, High Risk/High Reward Grants) Breakout Table | Golnaz Morad, D.D.S., Ph.D. |

| Annual Meeting Program All sessions rooms are in the George R. Brown Convention Center. | | As of Nov. 7 |
|---|--|------------------------|
| Friday, Nov. 8 | | |
| 10:00-10:30 a.m. | Meet the Experts: Phase I Clinical Trials: The Foundation of Cancer Drugs Stéphane Champiat, M.D., Ph.D., Jennifer Litton, M.D., and Aung Naing, M.D. | MD Anderson Booth 1027 |
| 10:30-11:00 a.m. | CAR T Cells and T Cell Bispecifics for Hematologic Malignancies Samer Srour, M.B.Ch.B. | |
| 11:00-11:30 a.m. | Meet the Experts: Immunotherapy for Prostate Cancer—What’s new? Sumit Subudhi, M.D., Ph.D., and Sumit Subudhi, M.D., Ph.D. | |

| | | |
|-------------------------|--|------------------------------------|
| 11:30 a.m.-noon | Meet the Experts: Learning from Our Patients—Translational Molecular Pathology Cara Haymaker, Ph.D., and Humam Kadara, Ph.D. | MD Anderson Booth 1027 |
| 12:15-1:45 p.m. | Lunch and Poster Viewing – See full poster list starting on page 3. | Level 1 - Exhibit Halls AB |
| 12:30-1:30 p.m. | Concurrent Session 105b: Rapid Oral Abstracts - Clinical | Level 3 - Grand Ballroom C |
| 1:00-1:08 p.m. | (1037) SARS-COV-2 mRNA vaccines are associated with Type I interferon signaling and improved clinical responses to immune checkpoint inhibition | Adam Grippin, M.D., Ph.D. |
| 1:08-1:16 p.m. | (1413) An integrated tumor, immune and genetic landscape of pleural mesothelioma to unleash effective immunotherapy avenues | Katarzyna Tomczak, Ph.D. |
| 1:45-3:20 p.m. | Concurrent Session 106b: Microbiome: Ready for Prime Time? | Level 3 - General Assembly Theater |
| | Co-Chair | Jennifer Wargo, M.D. |
| 2:02-2:17 p.m. | Microbial Cell Therapies: Challenges and Opportunities for Bugs as Drugs | Christopher Johnston, Ph.D. |
| 1:45-3:20 p.m. | Concurrent Session 106d: Biotech Breakthroughs—Solid Tumor IO at the Tipping Point | Level 3 - Grand Ballroom B |
| 2:45-2:55 p.m. | (1472) A phase I/II study evaluating the safety and efficacy of autologous TAC T cells in subjects with claudin 18.2+ advanced solid tumors | Ecaterina Dumbrava, M.D. |
| 1:45-3:20 p.m. | Concurrent Session 106e: Commonalities and Site-Specific Factors for Immune Microenvironments across and between Tumor Types | Level 3 - Grand Ballroom C |
| 1:45-2:05 p.m. | From the Clinic to the Lab: Investigating Mechanisms of Response and Resistance to Immune Checkpoint Therapy | Padmanee Sharma, M.D., Ph.D. |
| 2:00-2:30 p.m. | Meet the Experts: Managing Immune Checkpoint Inhibitor Side Effects Yinghong "Mimi" Wang, M.D., Ph.D. | MD Anderson Booth 1027 |
| 3:50-5:25 p.m. | Concurrent Session 107d: NK Cells and Innate Immunity | Level 3 - Grand Ballroom B |
| 3:50-3:51 p.m. | Co-Chair; Introduction | Katy Rezvani, M.D., Ph.D. |
| 4:13-4:35 p.m. | NK Cells: Next Generation Cell Therapies for Cancer | |
| 3:50-5:25 p.m. | Concurrent Session 107f: Focus on Latin American Immuno-Oncology | Level 3 - Meeting Room 332 |
| 5:03-5:13 p.m. | (1190) Neuromuscular immune-related adverse events and diaphragmatic insufficiency as mortality predictors in immune checkpoint therapy associated myocarditis | Keila Ostos-Mendoza |
| 5:30-6:00 p.m. | Meet the Experts: Emerging Frontiers in Cell Therapy Katy Rezvani, M.D., Ph.D. | MD Anderson Booth 1027 |
| 5:30-7:00 p.m. | Poster Reception – See full poster list starting on page 3. | Level 1 - Exhibit Halls AB |
| Saturday, Nov. 9 | | |
| 9:00-9:30 a.m. | Meet the Experts: Cold to Hot—Transforming Tumors for Improved Outcomes Xi Chen, Ph.D., and Michael Curran, Ph.D. | MD Anderson Booth 1027 |
| 10:00-10:30 a.m. | Meet the Experts: Advances in Thoracic Cancer and Immunology Marcelo Negrao, M.D., and Stephanie Schmidt, Ph.D. | |
| | Meet the Experts: James P. Allison Institute James Allison, Ph.D., and Padmanee Sharma, M.D., Ph.D. | |
| 10:30-11:30 a.m. | The Postdoctoral Experience at MD Anderson Mehdi Chaib, Ph.D., Cara Haymaker, Ph.D., Alexander Lazar, M.D., Ph.D., Golnaz Morad, Ph.D., Elise Nassif Haddad, M.D., Ph.D., and Jacqueline Oliva Ramírez, Ph.D. | |
| 11:30 a.m.-noon | Meet the Experts: Our Culture of Team Science Giulio Draetta, M.D., Ph.D., Eyal Gottlieb, Ph.D., Tim Heffernan, Ph.D., and Timothy Tap, M.B.B.S., Ph.D. | |
| | Meet the Experts: Innovations in Vaccine Research Adam Grippin, M.D., Ph.D., and Eduardo Vilar-Sanchez, M.D., Ph.D. | |
| 12:15-1:45 p.m. | Lunch and Poster Viewing – See full poster list starting on page 3. | Level 1 - Exhibit Halls AB |

| | | |
|------------------------|--|---|
| 12:30-1:00 p.m. | Meet the Experts: Institute for Data Science in Oncology Linghua Wang, M.D., Ph.D., and Jia Wu, Ph.D. | MD Anderson Booth 1027 |
| 12:30-1:30 p.m. | Session 205a: Rapid Oral Abstract-Basic | Level 3 - Grand Ballroom B |
| 12:30-12:38 p.m. | (896) VCAM-1+ tumor associated macrophages form perivascular tumor niches and drive resistance to anti-CTLA-4 therapy | Mehdi Chaib, Ph.D. |
| 1:16-1:23 p.m. | (1018) Leveraging innate immune sensors to generate durable anti-glioma adaptive immune responses | Spencer Lea |
| 12:30-1:30 p.m. | Session 205b: Rapid Oral Abstract-Clinical Co-Chair | Level 3 - Grand Ballroom C Golnaz Morad, D.D.S., Ph.D. |
| 1:08-1:16 p.m. | (1207) Artificial Intelligence-powered assessment of tumor microenvironment in pre-treatment and ontreatment biopsies informs treatment outcomes to pembrolizumab in patients with rare tumors | Mohamed Derbala, M.D. |
| 1:16-1:24 p.m. | (1242) Integrative machine learning for identifying treatment-specific impacts and biomarkers applied to multi-platform data from non-small-cell lung cancer treated with neoadjuvant chemoimmunotherapies | Stephanie Schmidt, Ph.D. |
| 3:25-4:45 p.m. | Session 207e: Modulating the Tumor Vasculature to Improve Immunotherapy | Level 3 -Grand Ballroom C |
| 4:35-4:45 p.m. | (900) An iron-rich subset of macrophages promotes tumor growth through a Bach1-Ednrb axis | Ian Folkert, M.D., Ph.D. |
| 5:15-6:35 p.m. | Session 208d: CAR-T cells vs T-cell Engaging Bispecifics in Hematological Malignancies | Level 3 - Grand Ballroom A |
| 5:55-6:15 p.m. | CAR T vs Bispecifics: Clinical Implications and Future Directions | Jason Westin, M.D. |
| 5:00-5:30 p.m. | Meet the Experts: The Latest in Melanoma Treatment Isabella Glitza Oliva, M.D., Ph.D. | MD Anderson Booth 1027 |
| 7:10-8:30 p.m. | Poster Reception – See full poster list starting on page 3. | Level 1 - Exhibit Halls AB |
| Sunday, Nov. 10 | | |
| 11 a.m.-12:35 p.m. | Session 302: Hot Topic Symposium: AI in Discovery | Level 3 - Hall A3 |
| 11:45 a.m.-12:05 p.m. | Machine Learning for Decoding Tumor Microenvironments and Predicting Patient Outcomes | Linghua Wang, M.D., Ph.D. |
| 12:05-12:35 p.m. | Panel Discussion | |

| | | |
|--|--|-----------------------------|
| Posters: View odd poster numbers on Friday, Nov. 8. View even poster numbers on Saturday, Nov. 9. | | |
| Abstract 1: Immunological effects of transarterial embolization using Ethiodized oil and unloaded microspheres as embolic agents | | Andrea Cortes |
| Abstract 25: Low-dose radiation-powered immunotherapy reshapes tissue nanomechanics: a tumor-agnostic approach to detect and restore tumor response | | James Welsh, M.D. |
| Abstract 90: Utilizing spatial transcriptomics to define potential biomarkers of immune checkpoint blockade in appendiceal cancer – a proof of concept pilot study. | | Eleanor Fallon, M.D. |
| Abstract 91: Using spatial multi-omics to investigate the contribution of tumor microenvironment to minimal residual disease and intrinsic chemoresistance of high-grade serous ovarian cancer | | Sammy Ferri-Borgogno, Ph.D. |
| Abstract 96: Spatial Analysis reveals differential immune cell interactions in Histologic Progression areas of Intraductal Papillary Mucinous Neoplasms of the Pancreas | | Sharia Hernandez, M.D. |
| Abstract 115: Utilization of a tissue-based PD1_PD-L1 in situ proximity ligation assay in lung adenocarcinoma (LUAD) and pleural mesothelioma | | Idania Lubo |
| Abstract 134: Tumor volumetric analysis to correlate disease burden with outcomes to adoptive cellular therapies in patients with advanced solid tumor | | Derrick Tao, M.D. |
| Abstract 157: Simultaneous high-throughput identification of driver mutation-derived public neoantigens and cognate functional T cell receptors | | Ho (Brandon) Ngai, Ph.D. |

| | |
|--|------------------------------------|
| Abstract 200: Impact of repeated metastasis-directed therapy (MDT) on circulating immune cells in patients with oligometastatic renal cell carcinoma (RCC) | Simin Kiany, Ph.D. |
| Abstract 205: Development of an Algorithm ('LS Finder') for Identifying Lymphoid Structures, TLS and Lymphoid Aggregates, Using Immune Cell Spatial Coordinates | Ayse Koksoy, Ph.D. |
| Abstract 216: Unbiased microfluidic isolation of antigen-specific T cells in solid tumors | Amanda Montoya |
| Abstract 222: Evaluation of a human tumor fragment culture as a model for testing immune-modulatory effects of therapeutic agents | Juan Amador Molina |
| Abstract 311: Identifying the potential contribution of cytokines in the cytotoxicity of CD70 directed Chimeric Antigen Receptor Natural Killer (CAR NK) cells against Osteosarcoma. | Ramya Ramakrishnan, M.D. |
| Abstract 322: ALLO-316 in patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC): Updated safety and efficacy from the phase 1 TRAVERSE multicenter study | Samer Srour, M.B.Ch.B. |
| Abstract 333: Agent-based modeling of tumor microenvironment dynamics in adoptive cell therapy | Yujia Wang |
| Abstract 343: Oncolytic viruses induce sustained anti-tumor cytotoxicity in NK cells | Xin Ru Jiang |
| Abstract 358: T cell receptor engineering targeting EGFR-mutant non-small cell lung cancer | Emily Bontekoe |
| Abstract 387: Identification of novel T cell receptor (TCR) target to Brachyury for the development of T cell-based immunotherapy of chordoma and other solid tumors | Ke Pan, Ph.D. |
| Abstract 399: Phase I dose escalation and expansion study of PRAME T-cell receptor engineered IL15-transduced cord blood-derived Natural Killer cells in patients with recurrent/refractory melanoma (PRAMETIME-Mel) | Derrick Tao, M.D. |
| Abstract 420: Elucidating the Role of MHC Class I and MHC Class II Tumor Antigen Presentation by CD103+ Dendritic Cell Vaccines | Josue Pineda |
| Abstract 423: Effective targeting of osteosarcoma by ex vivo expanded TCR $\gamma\delta$ T cells | Harjeet Singh, Ph.D. |
| Abstract 456: Functional and transcriptomic evaluation of pleural mesothelioma tumor expanded infiltrating lymphocytes and their TCR repertoire. | Jacqueline Oliva, Ph.D. |
| Abstract 472: Pathogenic B cells are associated with non-response to triplet combination of CTLA-4 and PD-1 blockers plus TNF- α inhibitor in mouse model of melanoma and colitis. | Glenn Winn |
| Abstract 474: Mechanistic Insights on Immune Checkpoint Inhibitor-Induced Recurrent Inflammatory Arthritis | Synat Keam, Ph.D. |
| Abstract 484: Clinical efficacy of immune checkpoint inhibitors in primary cardiac angiosarcoma | Aparna Subramaniam, Ph.D. |
| Abstract 516: Immune Checkpoint Inhibitors in Advanced Urachal and Non-Urachal Adenocarcinomas of the Urinary Tract: The MD Anderson Cancer Center Experience. | Mohammad Jad Moussa, M.D. |
| Abstract 528: Use of a novel antibody labeling method to track leukocyte migration into tumors following PD-1 immunotherapy | Oluwatoyosi Adewunmi, Ph.D. |
| Abstract 553: Depletion of effector regulatory T cells drives major response to induction dual immune checkpoint blockade (ICB) in patients with oropharyngeal carcinoma (OPC) | Xianli Jiang, Ph.D. |
| Abstract 564: Loss of PD-1 can improve the functionality of anti-tumor CD8 T cells through both direct cell-intrinsic and indirect cell-extrinsic mechanisms | Kristen Pauken, Ph.D. |
| Abstract 565: Multimodal spatial transcriptomics and proteomics analysis of the resectable NSCLC ecosystem following neoadjuvant chemoimmunotherapy | Zahraa Rahal, M.D. |
| Abstract 569: Cell-Specific Deletion of Bhlhe40 Reveals Distinct Mechanisms Underlying Anti-PD-1 and Anti-CTLA-4 | Akata Saha |
| Abstract 572: Single cell analyses reveal functional heterogeneity within an exhausted CD8+ TIL population that is correlated with response to checkpoint therapy in melanoma | Prachi Sao, Ph.D. |
| Abstract 575: Epigenetic Modulation by KDM6B in Myeloid Cells Regulates Glioblastoma Immune checkpoint therapy Outcomes | Pratishtha Singh, Ph.D. |
| Abstract 578: Defining immune and tumor resistant cell states to targeted vs immune therapy in non-small cell lung cancer (NSCLC) | Santiago Trevino |
| Abstract 638: Nous-209 vaccine induces shared neoantigen immunogenicity for cancer interception in healthy Lynch Syndrome carriers: results from Phase Ib/II trial | Eduardo Vilar-Sanchez, M.D., Ph.D. |

| | |
|--|--------------------------------|
| Abstract 641: ICT01 and pembrolizumab in combination elicit deep and durable responses in heavily pretreated patients with urothelial cell carcinoma: interim results from study EVICTION | Stéphane Champiat, M.D., Ph.D. |
| Abstract 646: A pilot presurgical trial of REGN5678 (Anti-PSMAxCD28) in patients with high-risk, localized prostate cancer followed by radical prostatectomy | Bilal Siddiqui, M.D. |
| Abstract 654: XMT-2056: A Phase 1 Study of a HER2-directed STING agonist Antibody Drug Conjugate (ADC) in HER2+ Solid Tumors | Ecaterina Dumbrava, M.D. |
| Abstract 660: A Phase 1/2 Study of KSQ-001EX: An autologous Tumor-Infiltrating Lymphocyte Therapy engineered to inactivate the SOCS1 gene in Patients with Select Advanced Solid Tumors | Rodabe Amaria, M.D. |
| Abstract 663: AdAPT-001, a first-in-class 2-in-1 TGF-beta inhibitor plus a checkpoint inhibitor: updated results from a Phase 2 study in solid tumors | Anthony Conley, M.D. |
| Abstract 675: VICTORIA-01: A multicenter, open-label, phase 1 study to evaluate the safety and preliminary efficacy of SOT201 in patients with advanced or metastatic solid tumors | Aung Naing, M.D. |
| Abstract 692: ICT01 and pembrolizumab in combination elicit deep and durable responses in heavily pretreated patients with refractory melanoma: interim results from study EVICTION | Stéphane Champiat, M.D., Ph.D. |
| Abstract 705L Hypoxia-activated prodrugs with distinct mechanisms of action sensitize murine prostate tumors to immune checkpoint blockade | Priyamvada Jayaprakash, Ph.D. |
| Abstract 733: Antitumor activity of CAR T cells potentiated by oncolytic adenoviruses armed with immune stimulators | Hong Jiang, Ph.D. |
| Abstract 748: Localized STING Agonist Delivery via Liposome-MDP Hydrogel Composites Plus Systemic α -PD-1 and α -CTLA-4 Improves Immunotherapy Responses | Andrea Molina |
| Abstract 749: Impact of Bintrafusp alpha and Radiotherapy in Intrahepatic Cholangiocarcinoma: Proteomic and Transcriptomic Analysis | Max Molina Ayala |
| Abstract 750: A biomarker signature differentiates immune status in patients with cold gastrointestinal tumors, predicting clinical benefit of NT-17 (efineptakin alfa, a long-acting interleukin-7) and pembrolizumab | Aung Naing, M.D. |
| Abstract 759: Immune checkpoint B7-H3 is a therapeutic vulnerability in prostate cancer harboring PTEN and TP53 deficiencies | Wei Shi, Ph.D. |
| Abstract 760: Activation of immune response with beta-glucan and CD40 agonist as a novel immunotherapeutic approach against osteosarcoma lung metastasis. | Pradeep Shrestha, Ph.D. |
| Abstract 774: Refocusing on tumors: overcoming antiviral immunity in oncolytic virotherapy | Dong Ho Shin |
| Abstract 787: Targeting DNA damage response modulates antiphagocytic signals to convert radiotherapy into a systemic immunotherapy to treat metastatic colorectal cancer | Broderick Turner |
| Abstract 808: Attacking Carbonic Anhydrase IX as a Gateway to Remodeling Tumor Hypoxia | Krithikaa Rajkumar Bhanu |
| Abstract 812: DRAGON Trial: Durable remission rate with the latent TGF β 1 inhibitor linavonkibart (SRK-181) and pembrolizumab in patients with immune checkpoint inhibitor resistant advanced cancers | Timothy Yap, M.B.B.S., Ph.D. |
| Abstract 820: Neoantigen Cancer Vaccines and Different Immune Checkpoint Therapies Each Utilize Both Converging and Distinct Mechanisms | Sunita Keshari, Ph.D. |
| Abstract 827: Viroimmunotherapy combined with acetylation suppression: Advanced therapeutics for pediatric diffuse midline gliomas | Akhila Parthasarathy |
| Abstract 837: Impact of liver metastasis on immunotherapy in patients with solid tumors | Betty Stephen, M.B.B.S. |
| Abstract 838: Outcomes of a Pilot Educational Program for Frontline Clinical Staff in Early Detection and Intervention in Immune-Related Adverse Events | Emily Wang, Pharm.D. |
| Abstract 847: The single-cell and spatial immune landscape of ovarian cancer | Yibo Dai |
| Abstract 864: Exploration of the circulating immune microenvironment stratified by breast cancer subtype | June Li |
| Abstract 872: Quaking modulates anti-tumor immunity by regulating antigen processing and presentation in dendritic cells | Yating Li |
| Abstract 876: Fibroblast-immune cell interactions conserved between the healing wound and tumors: their identification and implications for the anti-tumor immune response | Kenneth Hu, Ph.D. |
| Abstract 891: Defining Circulating Myeloid Cell Phenotypic States in Patients with Oligometastatic Cancer | Marina Medina-Rosales |
| Abstract 899: Spatial transcriptomics reveals heterogeneity of the intratumoral immune microenvironment within undifferentiated pleomorphic sarcoma and regions of perivascular tumor-associated macrophages | Ian Folkert, M.D., Ph.D. |

| | |
|---|------------------------------------|
| Abstract 909: Entinostat enhances NK cell efficacy against osteosarcoma lung metastases by improving cytokine production, trafficking, persistence and cytotoxicity. | Ariana Anjier |
| Abstract 926: Comprehensive single-cell immune profiling of tumor-infiltrating lymphocytes in acral melanoma | Tomoyuki Minowa |
| Abstract 931: PD-L1 and PD-L2 Confer Distinct Downstream Inhibitory Signatures Through the PD-1 Receptor in T Cells | Guillaume Trusz |
| Abstract 938: Comparative analysis of syngeneic oral cancer development in the murine heterotopic and orthotopic tumor microenvironments and draining lymph nodes | Gemalene Sunga |
| Abstract 986: Phase I dose-escalation trial of AMXT 1501 dicaprinate plus difluoromethylornithine: A dual agent approach targeting immunosuppressive polyamine metabolism | Sarina Piha-Paul, M.D. |
| Abstract 989: Single cell analysis unveils activation of innate immunity and selective expansion of effector CD8 T cells in melanoma in response to intratumoral CD40 agonist in combination with PD1 immunotherapy | Barbara Pazdrak |
| Abstract 996: Modulating tumor metabolism to overcome mechanisms of resistance to viroimmunotherapy in pediatric brain tumors | Marc Garcia Moure, Ph.D. |
| Abstract 977: Unlocking the Therapeutic Potential of Glioma Virotherapy: NONO and cGAMP as Key Regulators of Innate Immune Activation | Andrew Gillard |
| Abstract 1001: Targeting the immunometabolic factor AhR boosts glioma viroimmunotherapy | Andres Lopez-Rivas |
| Abstract 1055: Universal tumor antigens: Targeting NRP1 on tumors with an exogenous antigen-linked anti-NRP1 antibody results in antigen cross presentation and tumor killing by memory T cells | Anne Philips, M.D. |
| Abstract 1182: Multisystem immunotherapy-related adverse events among patients with breast cancer treated with immune checkpoint inhibitors. | Ashwathy Balachandran Pillai, M.D. |
| Abstract 1192: Immunotherapy related adverse events and clinical outcomes in adult solid tumor cancer patients on immune checkpoint inhibitors admitted to a tertiary medical center hospitalist medicine service | Cesar Simbaqueba Clavijo, M.D. |
| Abstract 1196: Unveiling immune evolution in lung pre-cancer through graph contrastive learning of spatial transcriptomics | Muhammad Aminu, Ph.D. |
| Abstract 1198: Deep Learning-Driven Pathomics Signatures Enhance Patient Stratification and Prognosis in mNSCLC Treated with Immune Checkpoint Inhibitors | Rukhmini Bandyopadhyay, Ph.D. |
| Abstract 1211: Characterization of transcriptional programs with translational implications in Natural Killer (NK) cells via single-cell data factorization and knowledge graph integration | Shan He |
| Abstract 1217: A novel transformer-based deep learning model for predicting binding interactions between HLA class I molecules and peptides | Kun Hee Kim |
| Abstract 1227: Predicting PD-L1 Expression from CT Scans Using Deep Learning to Guide Immunotherapy in Metastatic Non-Small-Cell Lung Cancer | Amgad Muneer |
| Abstract 1236: Machine Learning-Based Clinico-Genomic Prediction of Benefits to Add Chemotherapy to Immunotherapy in Metastatic Non-Small Cell Lung Cancer | Maliazurina Saad, Ph.D. |
| Abstract 1238: Predicting Lung Cancer Risk with CT Radiomics: Implications for Immunoprevention | Morteza Salehjehromi, Ph.D. |
| Abstract 1244: Deep Learning Prediction of Immune Checkpoint Inhibitor Induced Pneumonitis from Baseline CT Scans in Lung Cancer | Eman Showkatian |
| Abstract 1256: Delineating the role of the microbiome and tumor microenvironment interactions driving mucosal melanoma response and resistance to immune checkpoint inhibitor treatment | Florentia Dimitriou, M.D., Ph.D. |
| 1263 High-fiber diet induces favorable gut microbiota, reduces immunosuppression and inhibits lung cancer development | Manvi Sharma |
| Abstract 1457: Phase IB Study of Immunotherapy Combining Ex-Vivo Pre-Activated and Expanded Cord Blood NK Cells with Cetuximab in Colorectal Cancer Patients with Minimal Residual Disease: An Interim Report | Maria Pia Morelli, M.D., Ph.D. |
| Abstract 1483: Activity of IDP-023 Allogeneic g-NK Cells Without Antibody Targeting in First-in-Human Phase I/II Study in Patients with Advanced Multiple Myeloma or Non-Hodgkin Lymphoma | Krina Patel, M.D. |
| Abstract 1485: Randomized clinical trial of infliximab versus vedolizumab for immune checkpoint inhibitor related colitis | Yinghong Wang, M.D., Ph.D. |

Abstract 1489: REStoring lymphoCytes Using NKTR-255 after chemoradiothErapy in solid tumors (RESCUE):
Preplanned Interim Safety and Efficacy Analysis

Steven Lin, M.D., Ph.D.